MHLW Expedites the Reviews of Gilead's Remdesivir to Treat Patients with COVID-19 in Japan
Shots: Shots:
- Japan will fast-track a review of Gilead’s remdesivir to approve it for COVID-19 patients- following the US FDA’s EUA for the therapy. If approved- Remdesivir would become Japan's first recognized therapy for COVID-19
- For remdesivir- the health ministry will apply a special approval system to shorten the screen-time for the therapy. In late Apr- the government reported that remdesivir needs to be introduced for emergency use and fast-track the procedures to greenlight domestic sales of the therapy- under the pharmaceuticals and medical devices law
- Remdesivir was previously failed as an Ebola treatment and is being evaluated against COVID-19 due to its ability to disable the mechanism by which the viruses replicate itself. According to a study published by NEJM- the therapy is effective in ~70% patients with severe symptoms of COVID-19
Click here to read full press release/ article
Ref: The Japan Times | Image: Gilead
Related News: Gilead’s Remdesivir Receives the US FDA’s Emergency Use Authorization for the Treatment of COVID-19
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com